5.
Approval of minutes dated October 20, 2021
6.2.
Approval of the Interim Financial Statement for the month of October 2021
6.3.
Resolution FY22-12 Inducement Resolution for Reimbursement of Expenditures for Capital Improvements
6.4.
BHMC, Approval to Enter into New Cost Per Test Agreement with bioMerieux for Blood Culture Identification (ID) and Antibiotic Susceptibility Test (AST)